ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years
Xiaofeng Zhang
Matched on ORCID iD 0000-0003-2738-3286; OpenAlex author ID A5101742243. Sources: ClinicalTrials.gov.
Their work
- Papers
- 13 (first author 2, last author 4)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 1
- Collaborators
- 19
2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 4 papers · 2025: 4 papers, 1 trial
Papers 13
- Targeting RhoA expression with formononetin and salvianolic acid B to mitigate pancreatic cancer-associated endothelial cells changes. Co-author DOI 10.1016/j.jep.2024.118711↗
- Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated degradation. Co-author DOI 10.1016/j.phymed.2025.157245↗
- Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian randomization analyses. Last author DOI 10.1186/s12885-025-13976-6↗
- Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. Last author DOI 10.4251/wjgo.v17.i4.103311↗
- Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and activating dCK. Co-author DOI 10.1016/j.heliyon.2024.e28488↗
- Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress. Co-author DOI 10.1016/j.intimp.2024.113497↗
- Global research trends and hotspots between pancreatic cancer and diabetes from2004 to 2024: A bibliometric analysis Last author DOI 10.21203/rs.3.rs-4198735/v1↗
- Personalized three-year survival prediction and prognosis forecast by interpretable machine learning for pancreatic cancer patients: a population-based study a… First author DOI 10.3389/fonc.2024.1488118↗
- Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. Co-author DOI 10.1016/j.bcp.2023.115810↗
- Development and validation of a prognostic prediction model for iron metabolism-related genes in patients with pancreatic adenocarcinoma. Co-author DOI 10.3389/fgene.2022.1058062↗
- The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.800140↗
- Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in vitro. Last author DOI 10.7150/jca.65875↗
- Feasibility and safety of EUS-guided radiofrequency ablation in treatment of locally advanced, unresectable pancreatic cancer. First author DOI 10.4103/eus-d-21-00013↗
Trials 1
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hongzhang Shen · 7 shared papers, 2022–2025 · strength 1.63
- Paper Efficacy and safety of early pancreatic duct stenting for unresectable pancreatic cancer: A randomized controlled trial. DOI 10.4251/wjgo.v17.i4.103311↗
- Paper Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated … DOI 10.1016/j.phymed.2025.157245↗
- Paper Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and ac… DOI 10.1016/j.heliyon.2024.e28488↗
- Hangbin Jin · 4 shared papers, 2024–2025 · strength 1.02
- Paper Targeting RhoA expression with formononetin and salvianolic acid B to mitigate pancreatic cancer-associated endothelial… DOI 10.1016/j.jep.2024.118711↗
- Paper Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian ran… DOI 10.1186/s12885-025-13976-6↗
- Paper Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and ac… DOI 10.1016/j.heliyon.2024.e28488↗
- Dongchao Xu · 4 shared papers, 2022–2025 · strength 0.87
- Paper Daurisoline inhibits pancreatic cancer progression by direct binding to PPARα and blocking its ubiquitination-mediated … DOI 10.1016/j.phymed.2025.157245↗
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in… DOI 10.7150/jca.65875↗
- Qiang Liu · 3 shared papers, 2023–2025 · strength 0.70
- Paper Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian ran… DOI 10.1186/s12885-025-13976-6↗
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis. DOI 10.1016/j.bcp.2023.115810↗
- Weigang Gu · 3 shared papers, 2022–2024 · strength 0.66
- Paper Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and ac… DOI 10.1016/j.heliyon.2024.e28488↗
- Paper Global research trends and hotspots between pancreatic cancer and diabetes from2004 to 2024: A bibliometric analysis DOI 10.21203/rs.3.rs-4198735/v1↗
- Paper The Role of Feedback Loops in Targeted Therapy for Pancreatic Cancer. DOI 10.3389/fonc.2022.800140↗
- Yuxin Wang · 2 shared papers, 2024–2025 · strength 0.51
- Paper Complex interplay between type 2 diabetes mellitus and pancreatic cancer: insights from observational and mendelian ran… DOI 10.1186/s12885-025-13976-6↗
- Paper Global research trends and hotspots between pancreatic cancer and diabetes from2004 to 2024: A bibliometric analysis DOI 10.21203/rs.3.rs-4198735/v1↗
- Jianfeng Yang · 2 shared papers, 2021–2025 · strength 0.47
- Paper Targeting RhoA expression with formononetin and salvianolic acid B to mitigate pancreatic cancer-associated endothelial… DOI 10.1016/j.jep.2024.118711↗
- Paper Feasibility and safety of EUS-guided radiofrequency ablation in treatment of locally advanced, unresectable pancreatic … DOI 10.4103/eus-d-21-00013↗
- Yu Wang · 2 shared papers, 2022–2025 · strength 0.47
- Paper Targeting RhoA expression with formononetin and salvianolic acid B to mitigate pancreatic cancer-associated endothelial… DOI 10.1016/j.jep.2024.118711↗
- Paper Development and validation of a prognostic prediction model for iron metabolism-related genes in patients with pancreat… DOI 10.3389/fgene.2022.1058062↗
- Mengyao Tian · 2 shared papers, 2022–2024 · strength 0.43
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in… DOI 10.7150/jca.65875↗
- Hangbin Jin · 1 shared paper, 2025 · strength 0.33
- Min-Hui Sun · 1 shared paper, 2025 · strength 0.33
- Yan Chen · 1 shared paper, 2025 · strength 0.28
- Buwei Teng · 1 shared paper, 2024 · strength 0.26
- Jun Ma · 1 shared paper, 2024 · strength 0.26
- Qiaoxian He · 1 shared paper, 2024 · strength 0.23
- Jianfeng Yang · 1 shared paper, 2022 · strength 0.20
- Meidan Ying · 1 shared paper, 2023 · strength 0.19
- Qifeng Lou · 1 shared paper, 2021 · strength 0.19
- Wenhan Wei · 1 shared paper, 2022 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.